Allakos: Successful Midstage Trial Leads To Too High A Valuation [Seeking Alpha]
Last allakos, inc earnings: 11/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
Allakos: Successful Midstage Trial Leads To Too High A Valuation Allakos ( ALLK refers Last year, around the time of its IPO, somebody said that $40 is too high a price to pay for ALLK because it didn’t have a product and was far away from the market. So, we need to figure out: why was he proven wrong, and what makes this stock tick? Is this movement sustainable? Can new investors get a better entry price? How would the stock’s potential be like nearing approval? It seems that the principal support behind ALLK has been its proximity to Roche ( OTCQX:RHHBY AZN AK002 can get first past the post in getting orphan drug designation and perhaps a fast track. The company took advantage of the recent positive data readout and upsized the originally planned $200 million worth of shares to $350 million worth of shares. The market also moved high enough for it to price the offering at $77, slightly below the market bid. The next two years will see a catalyst every 4-5 months. Catalyst Top line d
[Read more]
| Impact snapshot | Event time: | ALLK | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ALLK alerts
ALLK alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLK alerts
High impacting Allakos, Inc news events
Weekly update
A roundup of the hottest topics
ALLK
News
- Allakos's SC lirentelimab shows encouraging action in early-stage study [Seeking Alpha]Seeking Alpha
- Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly UnderdiagnosedGlobeNewswire
- Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)GlobeNewswire
- Allakos Inc (NASDAQ: ALLK) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Mid-stage data on Allakos' lirentelimab published in New England Journal of Medicine [Seeking Alpha]Seeking Alpha
- More
ALLK
SEC Filings
- 10/26/20 - Form 8-K
- 10/26/20 - Form 8-K
- 10/21/20 - Form 8-K
- ALLK's page on the SEC website
- More